During the event, Ukrainian specialists in the field of respiratory diseases and otolaryngology made reports on the diagnosis and selection of therapy for patients with community-acquired pneumonia, chronic obstructive pulmonary disease and bronchial asthma. The conference was attended by more than 2,500 health professionals from all over Ukraine.
The report "New opportunities in the treatment of diseases of the upper respiratory tract in the COVID-19 pandemic" represented by Associate Professor of Otolaryngology of PL Shupyk NMAPE, Bil Bohdan Nazarovych has been of much interest to the conference participants. In his report, Bohdan Nazarovych has noted that today more than 40% of the world's population suffers from allergic diseases. Allergic diseases, such as allergic rhinitis, significantly impair the quality of life of patients and affect the cognitive sphere, such as memory, attention, thinking, sleep and daily activity of patients. The most dangerous is that the allergic rhinitis precedes bronchial asthma, which accompanies the patient throughout his life.
According to the protocols of the Ministry of Health of Ukraine in the treatment of allergic rhinitis it is necessary to pay attention first of all to the use of histamine H1 receptor antagonist and leukotriene receptor antagonist.
Clinical studies have shown that the combination of histamine H1 receptor antagonist (levocetirizine) and leukotriene receptor antagonist (montelukast) provides a more effective treatment for patients with allergic rhinitis, in contrast to the use of each drug separately.
Recently, a new medicinal product appeared on the Ukrainian market. This new medicinal product is Allerginol Plus, which includes a fixed combination of two components – levocetirizine – histamine H1 receptor antagonist and montelukast – leukotriene receptor antagonist, which enhance each other's action. The use of Allerginol Plus in patients with allergic rhinitis promotes a more pronounced clinical effect, which improves the quality of life of patients and increases treatment compliance.
Allerginol Plus is recommended for patients to reduce the symptoms associated with seasonal and perennial allergic rhinitis, and rhinitis in patients with bronchial asthma as well. Allerginol plus is prescribed for use after consulting your doctor. Adults and children over 15 years of age should take 1 tablet once a day in the evening, regardless of food intake. The course of treatment is 14 days *
Allerginol plus is a double power against allergies!
* Detailed information on the medicinal product can be found in the instructions for medical use of Allerginol plus. Registration certificate No.: UA / 14440/01/01